THAR: סך מכירות החברה tharimmune.com

Tharimmune, Inc. (THAR) is developing oncology drugs through strategic in-licensing of assets, which drives its growth dynamics. While portfolio diversification covers liver cancer and pruritus therapies, the lack of profitability leaves the business dependent on venture capital investments. The company's sales volatility clearly demonstrates this stage, and the value of 0.00 describes the current level of operating inflows, confirming the early-stage trial phase.

This indicator captures the aggregate daily cash flow from product sales, determining the real-time speed of operating income generation. By analyzing the sales dynamics of Tharimmune, Inc. (THAR), investors assess the stability of market share and the business's ability to generate liquidity without relying on borrowed funds. The metric is sensitive to consumer demand, where stagnating values signal a risk of capital freeze. For the biotech startup Tharimmune, Inc. (THAR), such volumes confirm the effectiveness of attracting talent into immuno-oncology.